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Cardiovascular disease (CVD) is the leading cause of death worldwide. According to the World Health Organization (WHO), an
estimate of 17.3 million people died from CVDs in 2008 and by 2030, the number of deaths is estimated to reach almost 23.6
million. Despite the development of a variety of treatment options, heart failure management has failed to inhibit myocardial
scar formation and replace the lost cardiomyocyte mass with new functional contractile cells. This shortage is complicated by the
limited ability of the heart for self-regeneration. Accordingly, novel management approaches have been introduced into the ﬁeld of
cardiovascular research, leading to the evolution of gene- and cell-based therapies. Stem cell-based therapy (aka, cardiomyoplasty)
is a rapidly growing alternative for regenerating the damaged myocardium and attenuating ischemic heart disease. However,
the optimal cell type to achieve this goal has not been established yet, even after a decade of cardiovascular stem cell research.
Mesenchymal stem cells (MSCs) in particular have been extensively investigated as a potential therapeutic approach for cardiac
regeneration, due to their distinctive characteristics. In this paper, we focus on the therapeutic applications of MSCs and their
transition from the experimental benchside to the clinical bedside.
1.Introduction
Ischemic heart disease and congestive heart failure together
are identiﬁed as the leading cause of death worldwide [1].
Myocardial infarction (MI, aka heart attack) occurs as a
result of cardiomyocytes death leading to loss of viable
myocytes, which lack endogenous repair mechanisms. If left
untreated, it will lead to ﬁbrous scar formation replacing
the damaged myocardium with subsequent congestive heart
failure (CHF) [2]. Despite, the development of a wide array
of treatment options, heart failure management has failed
to replace the lost cardiomyocyte mass with new contractile
cells. The main challenge facing treatment options is the
limited ability of the heart for self-regeneration [3]. This
led to the introduction of gene- and cell-based therapeutic
approaches to treat the damaged heart [4].
In an attempt to replace cardiomyocytes lost after
ischemia, cellular therapy/cardiomyoplasty has been rigor-
ously investigated in the last few years due to the potential
beneﬁts in patients with a variety of cardiac diseases such as
acute MI, stable coronary artery disease, and heart failure
[5]. The goals of cell-based therapies for cardiac diseases
are reliant on the primary pathology, whether it is myocar-
dial ischemia, cardiac dysfunction, or both. In myocardial
ischemia, cellular transplantation is expected to provide a
renewable source of proliferating, functional cardiomyocytes2 Stem Cells International
and simultaneously trigger neovascularization in order to
provide a novel network of blood vessels to support and
nourish the newly forming cardiomyocytes [4]. Experimen-
tal evidence has recognized numerous stem, progenitor, and
mature cells that can induce these mechanisms in vivo,
including embryonic stem cells (ESCs), unfractionated bone
marrow cells (BMCs) and mononuclear cells (BMMNCs),
hematopoietic stem cells (HSCs), mesenchymal stem cells
(MSCs), endothelial progenitor cells (EPCs), cardiac pro-
genitor cells, skeletal myoblasts, fetal cardiomyocytes, and
induced pluripotent stem cells (IPSCs) [6].
Embryonic stem cells (ESCs) are derived from the inner
mass of the developing embryo during the blastocyst stage.
Being the prototypical stem cell, these cells have exhibited
the highest potential for organ regeneration including the
heart [7, 8]. Recently, it has been reported that ESCs
can diﬀerentiate into cardiac precursor cells and stimulate
myocyte development [9]. On the other hand, their native
propensity for pluripotent proliferation increased the risk
of teratoma formation [10]. Another potential challenge for
their clinical use is immunological incompatibility as a result
of their allogenic origin [11]. In addition, some social and
ethical concerns have been raised due to the methods by
which they are obtained [8].
Unlike pluripotent embryonic stem cells, adult stem
cells exhibit a limited capability of diﬀerentiation. The
bone marrow represents a classic adult stem cell source,
containing diverse cell populations (e.g., HSCs, EPCs and
MSC) that are able to migrate and transdiﬀerentiate into
distinct phenotypes. However, the ability of these cells to
diﬀerentiate into cardiac myocytes is indecisive [12–15].
Additionally, hematopoietic stem cells (HSCs) are normally
recognized by the expression of CD34+ and CD133 cell
surface markers. HSCs have been broadly investigated and
successfully used clinically for bone marrow transplanta-
tion in a variety of hematologic disorders [16]. On the
other hand, endothelial progenitor cells (EPCs) represent
a heterogeneous population of cells that mainly exist in
the bone marrow (BM). These cells are thought to induce
neovascularization, possibly playing a vital role in vascular
homeostasis and even myogenesis [17].
Skeletal myoblasts (SM) were the ﬁrst cells to evolve into
clinical trials and injected into the ischemic myocardium
[18]. Despite the great potential that these cells had on
MI patients, the clinical trial was shut down due to the
development of serious ventricular arrhythmias in the
myoblast-injected hearts[19].Even though enhancements in
left ventricular (LV) function and volumes were reported,
they were not sustained [20–22]. Cardiac stem cells or
progenitor cells are the other cell types that have been
identiﬁed in human and mammalian hearts; these cells can
be obtained from surgical or endomyocardial biopsies and
clonally expanded in vitro. The exact origin of these cells
whether intracardiac or extracardiac is unknown and needs
to be precisely determined by lineage tracing experiments
[23–27]. These cells exhibit a high proliferative potential, but
thisdoesnotseemtobesuﬃcienttohealextensiveinjuriesas
that of MI [28, 29]. Recently a novel population of stem cells,
known as induced pluripotent stem cells (iPSCs), with the
characteristic properties of embryonic stem cells (ESCs) but
derived from regular somatic cells such as adult ﬁbroblasts
were discovered. These human-stimulated pluripotent stem
cells are developed through nuclear reprogramming, trans-
duction of stemness factors, and the ectopic expression of
pluripotency genes into ﬁbroblasts [30–35]. This innovative
approach oﬀers an alternative source of stem cell lines with
cardiogenic potential without the conﬂicts of using eggs or
embryos [16]; however the clinical applications need to be
further established [36, 37].
As described above stem cell-based therapy displays
excitingpromises forregeneratingthedamagedmyocardium
and treating heart failure. However, the optimal cell type
to achieve this goal needs to be further investigated. MSCs,
due to their distinctive characteristics properties, have been
extensivelyinvestigatedasanappealingtherapeuticapproach
for cardiac regeneration. In this paper we will focus on the
therapeutic applications of MSCs and their transition from
the experimental benchside to the clinical bedside.
2.Mesenchymal StemCells
In the 1970s, Friedenstein et al. showed that the bone
marrow contains a population of HSCs and an infrequent
population of stromal cells, which are now known as
mesenchymal stem cells (MSCs) [38]. They were the earliest
researchers to display the capability of MSCs to diﬀeren-
tiate into mesoderm-derived tissue and to recognize their
signiﬁcance in regulating hematopoiesis [39]. In the 1980s,
diﬀerent research groups further established that MSCs can
diﬀerentiate into osteoblasts, chondrocytes, and adipocytes
[40, 41]. Later in the 1990s, Wakitani et al. demonstrated
that MSCs can diﬀerentiate into a myogenic phenotype [42].
In 1999, Kopen et al. revealed that MSCs are even able
to transdiﬀerentiate into ectoderm-derived tissue [43]. In
the same year, Makino et al. reported for the ﬁrst time
the ability of mouse BM-derived MSCs to speciﬁcally form
cardiomyocytes in vitro [44], and later on Toma et al. showed
the same ﬁndings in vivo [45].
Furthermore, MSCs also exert immunomodulatory
eﬀects, and they do not elicit an immune response on
allogenic transplantation due to the inhibition of T-cell
proliferation [46]. MSCs are shown to express HLA (human
leukocyte antigen) class I, but not HLA class II on their
cell surface membrane [47]. Undiﬀerentiated as well as
diﬀerentiated MSCs do not show proliferative lymphocytic
immune responses upon allogenic transplantation [47].
MSCs have also been recognized for their possible role in
prophylaxis and treatment of graft versus host disease [48,
49]. The immunomodulatory properties of MSCs further
permit them for their clinical large-scale production and
allogenic transplantation [50].
2.1.Sources,Deﬁnitions,andTypesofMesenchymalStemCells.
MSCshavebeenidentiﬁedinalmosteverytissuetypesuchas
brain, spleen, liver, kidney, lung, BM, muscle, skin, adipose
tissue, thymus, aorta, vena cava, and pancreas of adult mice.
MSCs might be located in all postnatal organs [51, 52]; yetStem Cells International 3
the most abundant source is the BM [53]. So far, there is no
exact deﬁnition for MSCs; consequently, MSCs are generally
deﬁned functionally, rather than by the existence of speciﬁc
surface markers [53]. MSCs adhere to cell culture dishes
without expressing the surface markers that distinguish
the HSCs [54]. Despite the variation in characterizing a
particular phenotype among diﬀerent studies, it is normally
accepted that MSCs are negative for CD11b, CD14, CD31,
CD34, and CD45. However, they are positive for CD29,
CD44, CD73, CD105, CD106, and CD166 [2, 55–58]. MSCs
are an infrequent population in the BM, representing about
0.001–0.01% of total nucleated cells [59]. In culture they
possess a spindle-shaped ﬁbroblast-like appearance and the
capability of expanding noticeably in culture, sustaining
their multilineage potential [2]. These adherence criteria in
culture and potential of multilineage are the most frequently
established deﬁnitions of MSCs [53].
MSCs comprise several subpopulations, including, recy-
cling stem (RS) cells, multipotent adult progenitor cells
(MAPCs),humanBM-derivedmultipotent stemcells(hBM-
SCs), and cardiac stem cells known as cardiac stromal cells
(CStCs). Recycling stem (RS) cells represent the smallest,
highly dividing group of MSCs and are thought to be
the more primitive form [53]. Unlike MSCs, RS cells do
not express hematopoietic stem cell surface markers, but
they are unique compared to other MSCs in expressing
the stem cell factor receptor (c-kit) [60]. The multipotent
adultprogenitorcells(MAPCs)aredistinctfromotherMSCs
in being immortal in culture. MAPCs share with human
BM-derived multipotent stem cells (hBMSCs) their ability
to produce cell types from all three germ layers [61, 62].
hBMSCs were shown to engraft and diﬀerentiate to multiple
lineages in a rodent model of postinfarcted heart failure [63].
Recently, a trend towards using tissue speciﬁc stem cells has
led to the identiﬁcation of a novel type of cardiac stem cells
known as cardiac stromal cells (CStCs) [64]. Rossini et al.
wereabletoexhibitthediﬀerentiationabilitiesoftheseCStCs
and the conventionally used bone-marrow-derived MSCs
[64]. In this study, they showed that despite the fact that
CStCswerelessabletoacquiretheosteogenicandadipogenic
phenotypes,theywereabletoexpresscardiovascularmarkers
more eﬃciently. Moreover, CStC showed longer survival of
transplantedcellsintotheinfarctedheartandbetterabilityto
diﬀerentiateintocardiomyocytesthanbone-marrow-derived
MSCs [64].
2.2. Therapeutic Applications of Mesenchymal Stem Cells in
Cardiac Regeneration. During the last decade, there has
been growing interest in MSCs as a therapeutic approach
for treating MI, in comparison with the other cell types
considered for cardiomyoplasty. MSCs have exclusive prop-
erties that may translate into convenient and extremely
eﬀective cell therapy [2]. MSCs can be easily isolated with
a high expansion potential in culture providing the large
numbers of cells required for transplantation within a
short period of time. Their characteristic properties include
the following: (1) genetic stability, (2) compatibility with
tissue engineering principles, (3) reproducibility of features
betweendiﬀerentbonemarrowisolates,(4)theirpotentialto
triggerregenerationinvariousfundamentaltissuesincluding
the myocardium and neovascularization, (5) they have the
ability to home to the damaged tissue or inﬂammatory sites,
and (6) moreover their immunoregulatory properties could
allow their use as an allogenic treatment. MSCs can be
delivered systemically, for example, via IV injection, which
simpliﬁes administration without the necessity for cardiac
catheterization laboratories. These cells can be readily trans-
duced by a range of vectors and retain transgene expression
after in vivo diﬀerentiation, which might be used eventually
to enhance cell engraftment or the degree of diﬀerentiation
[2, 4, 53].
3. Mesenchymal Stem Cell Therapy: Benchside
In the ﬁeld of MSC transplantation into cardiac tissue,
animal models mostly focus on fate, eﬃcacy, regenerative
mechanisms, and the safety of transplanted MSCs. In line
with the increased incidence of myocardial infarction, both
small and large animal models have been used in large
numbers, providing the proof of functional eﬀectiveness,
pathomechanisms, and safety of MSC transplantation [65].
In this context, it has been reported that BM cells were used
for the ﬁrst time for cardiomyoplasty in 1999 by the labora-
tories of Tomita et al. [66]. In this paper, rats received autol-
ogous BMCs via direct intramyocardial injection at 3 weeks
after cryoinjury. Eight weeks postcryoinjury researchers were
able to identify transplanted BMCs in all animals. They
found that these cells expressed muscle-speciﬁc proteins that
were absent prior to implantation. Moreover, they reported
improvements in systolic and diastolic functions in animals
that received cells pretreated with the DNA-demethylating
agent 5-azacytidine (5-Aza), which has been established
to augment myogenic diﬀerentiation of pluripotent stem
cells [44]. Thereafter, numerous preclinical studies reported
improvement of left ventricular (LV) function, decreased
infarct size, and decreased mortality rate after transplanta-
tion of MSCs in mice [65, 67–71], rats [72–79], swine [80–
92], canine [93, 94], and sheep [78, 95] after acute or chronic
MI. These enhancements were observed even with minimal
percentage of cells exhibiting cardiomyocytes diﬀerentiation
[65, 70, 94]( Table 1).
Due to the anatomical similarity to the human heart,
swine heart has been chosen as a model for studies related
to MI and general cardiovascular studies [96]. This model
has been used to acquire signiﬁcant information on the
tracking of transplanted MSCs in healthy and infracted
myocardium and the immediate and long-term eﬀects after
engraftment [97]. In the swine model, Shake et al. reported
strong engraftment of labeled MSCs along with coexpres-
sion of numerous muscle-speciﬁc proteins as early as two
weeks after intramyocardial implantation. This study pro-
posed that the diﬀerentiation of MSCs into cardiomyocyte-
like cells occurs two weeks after transplantation, followed
by a signiﬁcant improvement of contractile dysfunction
and wall thinning [92]. A similar study by Schuleri et
al. showed that intramyocardial transplantation of MSCs4 Stem Cells International
Table 1: Eﬀects of MSC therapy on both small and large animal models of MI. MI, myocardial infarction; DI, direct intramyocardial
injection; IV, intravenous infusion; IS, in situ injection; TESI, transendocardial stem cell injection; IC, intracoronary infusion; LV, left
ventricular; EF, ejection fraction; ESV, end-systolic volume; EDV, end-diastolic volume; ↑, increase; ↓, decrease. ∗The monolayered cell
graft was placed on a plastic sheet and applied face down onto the surface of the infarct area. The plastic sheet was then carefully removed,
leaving the monolayered cell graft on the surface of the heart.
Species/model Dose Results Reference
Mice
Acute MI 0.5–5 ×105 (DI) ↓ Both infarct size and ﬁbrosis at 2 weeks Kudo et al. [68]
Acute MI 3 ×105 (DI) ↑ Cardiac function at 4 weeks Fazel et al. [65]
Acute MI 5 ×105 (DI) ↓ Infarct size; ↑ cardiac function at 3 days Noiseux et al. [70]
Acute MI 1 ×106 (DI) ↑ LVEF at 2 and 4 weeks Nakamura et al. [69]
Acute MI 1 ×106 (DI) ↑ Cardiac function at 1 month Shiota et al. [71]
Acute MI 2 ×105 (DI) ↑ LVEF and LV function at 2 weeks Grauss et al. [67]
Rats
Acute MI 5 ×106 (DI) ↓ Cardiac remodeling; ↑ cardiac performance at 2 weeks Mangi et al. [77]
Acute MI 5 ×106 (IV) ↑ Cardiac function; ↓ infarct size at 4 weeks Nagaya et al. [79]
Acute MI 2 ×106 (DI) Transient global LV function improvement at 4 weeks Dai et al. [73]
Acute MI 2 ×106 (DI) ↓ Fibrosis; ↑ cardiac function at 8 weeks Berry et al. [72]
Acute MI Cell graft
∗ Reversed wall thinning; ↑ cardiac function at 8 weeks Miyahara et al. [78]
Acute MI 6 ×106 (DI) ↑ LVEF; ↓ infarct size at 3 weeks Li et al. [76]
Acute MI 1 ×106 (IS) ↑ LVEF; ↓ infarct size at 30 days de Macedo Braga et
al. [74]
Acute MI 5 ×106 (DI) ↑ LVFS; ↓ ﬁbrosis at 4 weeks Imanishi et al. [75]
Swine
Subacute MI 6 ×107 (DI) ↓ Wall thinning in the scar area; ↑ cardiac function at 4 weeks Shake et al. [92]
Acute MI 2 ×108 (TESI) ↓ Necrotic myocardium; ↑ cardiac performance over 8 weeks Amado et al. [80]
Chronic MI 2 ×108 (DI) Preserved LVEF at 60 and 90 days post-MI Makkar et al. [86]
Acute MI 2 ×108 (TESI) ↓ Infarct size at 1 and 8 weeks; restored contractile function Amado et al. [81]
Acute MI 3.2 ×108 (IV) ↑ LVEF; ↓ hypertrophy at 3 months Price et al. [87]
Subacute MI 6.3 ×105 (TESI) ↓ Scar size; ↓ EDV; ↑ LVEF at 10 days Gyongyosi et al. [82]
Chronic MI 1–10 × 106 (IV)
↑ Vasculogenesis; ↑ regional perfusion; no change in LVEF at
12 weeks Halkos et al. [83]
Acute MI 0.24–4.4 × 108 (TESI) ↓ Scar size; no change in LVEF at 12 weeks Hashemi et al. [84].
Acute MI 1 ×107 (IC) ↑ EF; ↓ scar size at 8 weeks Qi et al. [88]
Acute MI 2 ×108 (TESI) ↑ Myocardial blood ﬂow at 1 week; ↑ LV function at 8 weeks Schuleri et al. [90]
Chronic MI 2 ×108 (TESI)
↓ Scar size; ↑ EF; ↑ regional contractility; ↑ myocardial
perfusion over 12 weeks Quevedo et al. [89]
Chronic MI 0.2–2 ×108 (DI)
↓ Scar size; ↑ EF; ↑ regional contractility; ↑ myocardial
perfusion at 12 and 24 weeks Schuleri et al. [91]
Acute MI 0.75–1 ×108 (TESI) ↓ Scar size; ↑ EF at 2 and 8 weeks Hatzistergos et al.
[85]
Canine
Chronic
ischemia 1 ×108 (DI) ↓ Fibrosis; ↑ LVEF at 60 days Silva et al. [94]
Subacute MI 1 ×108 (IC/TESI)
↑ EF; ↓ myocardial ischemia; ↓ EDV and ESV at 21 days
post-MI Perin et al. [93]
Sheep
Acute MI 25–450 ×106 (DI)
↓ Infarct expansion; ↑ vascular density in the border zone; ↑
EF; ↓ EDV at 8 weeks Hamamoto et al. [95]Stem Cells International 5
resulted in a signiﬁcant increase of LV function eight
weeks after transplantation [90]. These improvements were
preceded by an early enhancement of resting myocardial
blood ﬂow after one week, which was conﬁrmed by an
increase in vessel size in the MSC group versus the control
groups. These observations suggest that transplantation of
MSCs can ameliorate cardiac function by reducing infarct
size, triggering neovascularization and cardiomyogenesis
(Table 1).
The optimization of safety and possible procedures
for cell delivery are central issues to be considered in
cardiomyoplasty. By using large animal models (i.e., swine,
dogs, sheep), the majority of investigators have revealed
that the intramyocardial injection of progenitor cells across
the infarcted region is safe and possible [97]. For example,
experiments on the swine model showed that intramyocar-
dial injection of MSCs (range: 104–108 cells) is safe and
does not result in any obvious immune or toxic response
[92, 96, 98–100]. On the other hand, studies on dose-
dependent eﬀects have displayed no relevant results to date
[84]. Also, “oﬀ the shelf” application of allogenic MSCs in a
swine safety study with repeated intramyocardial injections
of high doses of MSCs (up to 800 × 106 cells) was devoid of
adverse eﬀects in terms of sustained ventricular arrhythmia,
anaphylaxis, or myocardial damage [101]. Additionally, the
procedural safety of the intramyocardial injection process
was demonstrated in a canine chronic ischemia model. Dogs
that received intramyocardial injections of MSCs (1 × 108
total cells) tolerated the procedure without exhibiting any
complications such as cardiac arrhythmias or myocardial
damage [94].
On the other hand, intravenous infusion of MSCs in
swine changed the electrophysiological properties of the
myocardium [87].Inthisstudy,therewassigniﬁcantincrease
in cardiac function and decrease in eccentric hypertrophy;
however, there was also a shortening in epicardial eﬀective
refractory periods in MSC-treated animals in comparison
with placebo. Shortened eﬀective refractory periods might
trigger ventricular tachycardia [102] and increase the pos-
sibility of MSCs to trigger proarrhythmic remodeling. In
contrast to these observations in swine, intravenous infusion
of allogenic MSCs in humans with acute MI revealed fewer
ventricular arrhythmias than in those with placebo infusion
[103]. These studies revealed that intravenous allogenic
MSCs are safe in patients with acute MI. Likewise, MSC
therapy in other clinical trials was not associated with any
adverse eﬀects [104, 105].
In addition to cardiac arrhythmia and myocardial dam-
age, a number of reports have raised concerns about tumor
formation as a result of using BM-cultured MSCs. In these
reports murine-derived BM-MSCs exhibited chromosomal
abnormalities that led to tumor formation in many organs
[106, 107]. In addition, a recent report revealed that both
MSCs and BM-derived stem cells have been associated with
calciﬁcation and probably ossiﬁcation of the heart in a
murine model of MI [108]. In contrast to these observations,
numerous large-animal preclinical studies displayed the
safetyofMSCstherapyandaredevoidoftumorformationor
ectopic tissue growth [80, 81, 83–87, 90, 91, 94]. Moreover,
data from early-phase human studies using MSCs showed
no evidence of ectopic tissue growth [103–105]. Even so,
the data of tumorigenesis in murine models emphasizes
the necessity of persistent long-term monitoring of patients
treated with MSCs. Furthermore, other reports have shown
that intracoronary injection of MSCs in canine and swine
models of MI resulted in microinfarctions and slow coronary
arterial ﬂow, respectively [109, 110]. Microvascular obstruc-
tion with intracoronary MSCs injection may be explained
by the fact that the size of MSCs is larger than other stem
cell types and their characteristic adherence to plastic in vitro
[53]. Nonetheless, this does not appear to be a problem in
the limited clinical experience, so far [53].
In summary, MSC therapy has been shown to be safe
and eﬀective in improving LV function, decreasing scar size,
and increasing myocardial tissue perfusion and angiogenesis
in post-MI small and large animal models. Yet, it is hard
to evaluate the impact of these preclinical studies on MI
patients. In regard to eﬀectiveness of MSCs, data displaying
a time-dependent retention, engraftment, migration, and
diﬀerentiation support the notion that MSC implantation is
analternativetherapeuticapproachforischemicheartfailure
[97]. Considering procedural safety, it could be presumed
that the reliable security ﬁndings displayed by the swine
studies may be applicable to humans [111]. Nevertheless, it
is clear that further studies are needed.
3.1. Modiﬁcation of Mesenchymal Stem Cells for Cardiac
Therapy. Regardless of the beneﬁts of MSCs, clinical appli-
cation of MSC-based therapy is restricted. This restriction
is attributed to the poor viability of the transplanted cells
in the myocardium [29]. Recent reports on a swine model
of MI displayed that only 5% of implanted MSCs can
survive for 14 days in the infracted myocardium [109]. In
addition, Toma et al. showed that the survival rate of the
implanted hMSCs in an intact mouse heart is less than 0.5%
at 4 days after transplantation [45]. Analogous outcomes
were also obtained from studies using diverse cell types.
Accordingly,cellviabilitypossesamajorobstacleforanycell-
based therapeutic strategy in the infarct heart [29]. Secondly,
reactive oxygen species (ROS) is known to be a key mediator
in cardiac dysfunction. ROS is known to hinder cell adhesion
and stimulate cell detachment and death [112–115]. Third,
the grafted cell may encounter ischemic conditions lacking
nutrientsandoxygenandconsequentlyaﬀectingcellviability
[116, 117]. On the other hand, myocardial injury has
been shown to generate a strong inﬂammatory response
followed by production of oxygen-derived free radicals and
inﬂammatory cytokines that trigger cell death and initiate
apoptosis[118].Despiteallthese,MSCsmayreactdiﬀerently
in the allogenic settings due to their previously described
immunomodulatory eﬀects on inﬂammatory cells [29].
To overcome the low cellular survival and transdiﬀer-
entiation strength of MSCs after transplantation, several
strategies have been proposed for MSCs manipulation
(Figure 1). Pretreatment with growth and diﬀerentiation
factors to expand the stem cells and facilitate their engraft-
ment into cardiac tissues has been attempted [25, 119–
121]. Also pretreatment with pharmacological agents such as6 Stem Cells International
estrogen, which inﬂuences myocardial remodeling through
stimulating growth hormone production in BM-MSCs and
EPCs [122] or through atorvastatin which enhances cell
survival and diﬀerentiation into cardiomyocytes [123]. More
recently, our group has demonstrated that combined treat-
ment of rats with stem cells and pharmacological hyperbaric
oxygen (HBO) treatment led to enhanced cell engraftment
and decreased ﬁbrosis at four weeks after transplantation
[55, 124]. Furthermore, stem cell preconditioning prior to
transplantation, such as hypoxic preconditioning, has been
shown to activate the Akt signaling pathway and the heat
shock protein (Hsp-70), therefore, maintaining cell viability
and cell cycle rates [125, 126]. Moreover, overexpression of
anti-cell-death signals or signals that improve cell adhesion
resultedinbetterrecoveryandadhesionaftertransplantation
[76, 77, 127–137].
Additionally, recent studies have shown that microRNAs
(miRNAs) are one of the key modulators in stem cell
diﬀerentiation. MiRNAs regulate gene expression in stem
cells that control its fate, function, and behavior. The
most important change in ESCs by miRNAs is the cell
diﬀerentiation,itwasshownthat miR-21,miR-134,an dmiR-
470 target certain genes to promote cell diﬀerentiation [138–
140]. At the same time, stem cell transcription factors and
silencing complexes bind to miRNAs promoter region and
regulate their expression during early cellular diﬀerentiation.
In murine ESCs, the most abundant miRNAs was miR-17-92
cluster and miR-302 that have been key regulators of cellular
proliferation [141–143]. It is worth mentioning that these
miRNAs are involved in maintaining DNA methylation and
facilitating repression and overexpression of certain genes
through diﬀerentiation and development [144]. Recent ﬁnd-
ings have shown that miR-150 regulates the mobilization and
migration of bone marrow mononuclear cells by targeting
CXCR4 [145].
4 .M e s e nc h ym alS t e mC ellT h e rap y:Bed s id e
For any particular type of cell-based therapy to be translated
from the preclinical benchside to the clinical bedside, Murry
et al. [146] proposed speciﬁc criteria; ﬁrst preclinical reve-
lation of safety and eﬃcacy should be evident reproducibly
in manifold laboratories. The inability of professionals in
a well-controlled laboratory to reproduce certain ﬁnding
means that the probability of such treatment to succeed
in the more capricious world of human clinical trials is
low, understanding the mechanisms of action to a logical
extent is also necessary, and especially the mechanisms by
which cell therapy causes functional improvements will help
in designing rational experimental and/or clinical studies
to improve the treatment eﬀectiveness. Cell-based therapy
should be validated in a scaled-up, physiologically pertinent
large animal model whenever possible. Regardless of the
advantages of small animals, several features of human
cardiovascular physiology cannot be reproduced in these
animal models. For instance, recognition of pacemaker
activity in stem cell transplants could be prevented by the
high heart rate of mice or rats, while implanting the same
cells into a larger animal model such as dogs, pigs, or sheep
could allow the detection of such complications [146].
Although the exact mechanisms of MSCs therapy are
not well deﬁned, prosperity of preclinical studies show-
ing the feasibility, eﬃcacy, and safety of such therapy as
mentioned above paved their way to enter the clinical
trials for human cardiac regeneration. However, variations
among diﬀerent laboratories in using diverse sources of
tissues, methods of extraction, protocols for culturing, and
tools for characterization led to many debates about the
characteristics and potencies of MSCs. These disparities may
cause isolation and expansion of distinct subpopulations of
cells or may alter the cell characteristics [147]. For example,
comparing MSCs cultivated in human supplements to those
cultured in fetal bovine serum (FBS) demonstrated that FBS
modiﬁes the expression of genes involved in diﬀerentiation
and adhesion/extracellular matrix to some extent [50, 147].
Furthermore, insuﬃciency of MSCs regularly necessitates ex
vivoexpansion;however,widespreadexpansionmayresultin
futile or collapsed cells [148].
Further, clinical trials using MSCs that are obtained and
characterized by a number of diverse protocols may limit
the reproduction or the elucidation of the clinical ﬁndings
[149]. Therefore, the challenge for researchers intending to
produce MSCs for clinical trials is to delineate the ﬁnest
cell culture conditions for eﬃcient isolation and ex vivo
expansion of homogenous MSCs along with maintaining
the cellular characteristics needed for the planned clinical
application and diminishing possibilities of undesirable
side eﬀects at the same time [50]. This requires that the
whole MSC manufacturing process from starting material
until potency testing for the planned clinical application
should be extremely standardized to obtain the required and
reproducible cellular characteristics and potencies [50]. In
this regard, using adult stem cell types in clinical studies,
normally, needs formal approval by the respective regulatory
body. This approval entails that cellular products should
be manufactured, processed, and tested according to the
present national guidelines, including present good tissue
practice (GTP), good manufacturing practice (GMP), and
good clinical practice (GCP). Applying these regulatory
frameworksonthecellularproductswillguaranteethesafety,
purity, and potency of these products and the feasibility of
their use in clinical application [50].
In comparison with the BMCs, the clinical involvement
of MSCs for cardiac regeneration remains in its early stages
and only a few number of phase I/II clinical studies have
been reported [150]. Table 2 summarizes some of the MSC
clinical trials in diﬀerent cardiac pathologies including MI,
chronicischemia,andheartfailure.In2004,Chenetal.[104]
investigated for the ﬁrst time the outcomes of intracoro-
nary injection of autologous BM-MSCs (8–10 × 109 cells)
in acute MI patients. At three-month followup, marked
enhancements in myocardial perfusion, LV ejection fraction,
and LV chamber dimensions were evident in MSC-treated
patients in comparison with placebo. Notably, this paper
displayed that MSC therapy is safe and devoid of deaths
and arrhythmias during the follow-up period. Similarly,
in 2005, Katritsis et al. [151] investigated the eﬀect ofStem Cells International 7
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Pharmacological
(1) Atorvastatin (Yang et al., 2008)
(2) Estrogen (Ray et al., 2008)
(3) Hyperbaric oxygen therapy
(Khan et al., 2009, 2012)
Modulated factors
(1) BMP-2, IGF-1, FGF2
(Hahn et al., 2008)
(2) HGF (Guo et al., 2008)
(3) IGF-1 (Koﬁdis et al., 2004)
(4) SDF-1 (Pasha et al., 2008)
(1) ↓ Infarct size and apoptosis; ↑ cardiac function
(2) ↑ Antiapoptosis, angiogenesis, and cardiac function
(3) ↑ Engraftment, diﬀerentiation and cardiac function
(4) ↓ Apoptosis; ↑ engraftment and vascular density
(1) Cell survival ↑
(2) ↓ Remodeling and ﬁbrosis
(3) ↑ Engraftment and cardiac function
(1) ↑ Cardiac protection and function
(2) ↑ Survival of engraftment
Transfection:
(1) Bcl-2 (Li et al., 2007)
(2) FGF-2 (Song et al., 2005)
(3) tTG (Song et al., 2007)
(4) VEGF (Markel et al., 2008)
(Yang et al., 2007)
Viral transduction
(1) Akt (Mangi et al., 2003)
(2) Akt, Ang-1 (Shujia et al., 2008)
(3) CXCR4 (Cheng et al., 2008)
(4) HO-1 (Zeng et al., 2008)
(5) ILK (Song et al., 2009)
(6) TNFR (Bao et al., 2008)
(7) VEGF (Gao et al., 2007)
(Matsumoto et al., 2005)
(I) Pretreatment
(I) Gene overexpression
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(1) ↑ Capillary density; ↓ infarct size and apoptosis
(2) ↑ Antiapoptotic genes and angiogenesis
(3) ↑ Adhesion and cell survival
(2) ↑ Functional and structural improvements
(3) ↑ Cardiac function and cell survival
(4) ↓ Apoptosis;↑ microvessel and cardiac function
(5) ↑ Adhesion; ↓ infarct size
(6) ↑ Cardiac function
(7) ↑ Angiogenesis; ↓ infarct size
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2
3
4
5
45
12
3
(4) ↑ Myocardial recovery and ↑ myocardial perfusion
(1) ↓ Infarct size; ↑ cardiac function and cell survival
Figure 1: Illustration of MSC modiﬁcations and its eﬀect after transplantation on engraftment, cell survival, apoptosis, cardiac function,
ﬁbrosis, and angiogenesis in animal models of MI.
Table 2: MSC clinical trials in MI, chronic ischemia, and heart failure. MI, myocardial infarction; IC, intracoronary infusion; DI, direct
intramyocardial injection; IV, intravenous infusion; TESI, transendocardial stem cell injection; EMG; electromechanical guidance; LV, left
ventricular; EF, ejection fraction; ESV, end-systolic volume; EDV, end-diastolic volume; ↑, increase; ↓, decrease.
Group Condition Dose (cells) Followup
(months) Results
Chen et al. [104] Acute MI 8–10 ×109 (IC) 3
↑ Myocardial perfusion, ↑
LVEF, and ↓ LV chamber
dimensions
Katritsis et al. [151] Anteroseptal MI 2–4 × 106 (IC) 4
↓ Wall motion score index
and ↑ myocardial viability
and contractility
Mohyeddin-Bonab et al.
[153] Old MI 2.1–9.1 × 106 (IC)/(DI) 6–18
↓ Perfusion defect and ↑
LVEF
Osiris therapeutics [146]A c u t e M I ( I V ) 6
↑ Heart function and ↓
arrhythmic events
Hare et al. [103] Acute MI 0.5, 1.6, and 5 × 106 (IV) 3
↑ LVEF and ↓ ventricular
arrhythmia
Williams et al. [105] Chronic ischemic
cardiomyopathy secondary to MI
10 repeated injections of 0.5mL
of cell suspension (TESI) 3–12
↓ Cardiac remodeling, ↓
ESV and EDV, and ↑
regional contractility
Bartunek et al. [154]
(C-CURE)
Heart failure secondary to
ischemic cardiomyopathy 6–12 ×108 (EMG) 6 ↑ LVEF and ↓ ESV and EDV8 Stem Cells International
a combination of intracoronary transplantation of BM-
derived MSCs and EPCs (2–4 × 106 cells) on tissue repair
in myocardial scars of patients with an anteroseptal MI. At
four-month followup, they reported a signiﬁcant decrease
in wall motion score index and signiﬁcant increases in
myocardial viability and contractility in stem-cell treated
patients compared to untreated controls. Moreover, the
investigators chose only ﬁve patients into their series who
had implantable cardioverter deﬁbrillator (ICD) to examine
the potential proarrhythmic eﬀect of MSC therapy [152]. At
16–36-month followup, assessment of the ICD showed that
none of the MSCs-treated exhibited either sustained or non-
sustained ventricular arrhythmia. Finally, they concluded
that intracoronary transplantation of MSCs and EPCs is
feasible, safe, and may participate in regional myocardial
regeneration following MI.
Mohyeddin-Bonab et al. [153] investigated the safety and
feasibility of MSCs therapy in a pilot study of eight patients
with old MI. MSCs (2.1–9.1 × 106 cells) were injected
either intracoronary in patients undergoing revasculariza-
tion by percutaneous coronary intervention or by direct
epicardial injection in patients undergoing revascularization
by coronary artery bypass graft surgery. At 6–18-month
followup, they revealed smaller perfusion defect, better LV
ejection fraction, and enhanced heart failure functional class
without reporting any adverse side eﬀects. Therefore, MSC
therapy was described to be safe and feasible in patients
with old MI. In 2008, Osiris Therapeutics [146] announced
the preliminary results of the ﬁrst clinical trial of MSC
transplantation for cardiac regeneration in the United States.
Patients received allogenic MSCs transplants by intravenous
infusion. At 6-month followup, MSC-treated patients exhib-
ited improvement in the heart and lung function along with
decreased arrhythmic events compared to placebo group.
The researchers reported that such allogenic cell products
did not necessitate prolonged cell pretreatment handlings;
however they are readily accessible to fulﬁll the clinical
community requirements [150]. A recent study by Hare
et al. [103] performed a double-blind, placebo-controlled,
dose-ranging (0.5, 1.6, and 5 × 106 cells/kg) safety trial of
intravenous allogenic MSCs in acute MI patients. Results
of this study demonstrated the safety of such intervention
in post-MI patients. It also demonstrated a decrease in
ventricular arrhythmias, enhanced pulmonary function, and
increased LV ejection fraction in MSC-treated patients after
3 months.
In 2011, Williams et al. [105] examined the functional
eﬀects of transendocardial injection of MSCs in patients
with chronic ischemic cardiomyopathy secondary to MI. In
this study MSC-treated patients exhibited decreased cardiac
remodeling and enhanced regional contractility along with
decreased end-diastolic and end-systolic volumes, at 3
months following stem cell injection and continued up to
one year. Notably, there was no evidence of ectopic tissue
growth or sustained arrhythmias at one year after trans-
plantation. This data indicates not only the safety of MSC
therapy for post-MI transplantation but also the eﬃcacy of
such therapy in modulating cardiac structure and function.
Most recently, Bartunek et al. [154] reported the results
of the C-CURE clinical trial for the treatment of ischemic
cardiomyopathy. In this study, guided cardiopoietic-MSC
therapy was delivered to viable but defective myocardium
by electromechanical guidance. At 6-month followup, the
results showed signiﬁcant enhancements in clinical perfor-
mance and ejection fraction, compatible with improvement
in end-diastolic and end-systolic volumes in cardiopoietic-
MSC therapy group compared to controls. Importantly,
evidence of cardiopoietic MSC-induced arrhythmias or
toxicity was absent.
Furthermore, a number of other clinical trial eﬀorts
are on track. Consistent with the registered data from
http://www.clinicaltrials.gov, a web-based service by the
National Institutes of Health of the United States, there are
ten ongoing phase I/II trials to evaluate the eﬃcacy and/or
safety of MSCs therapy for cardiac regeneration in diverse
places in the world including the United States, Europe, and
East and South Asia (Table 3). These studies are using diﬀer-
ent interventions for applying autologous and/or allogenic
MSCs in the treatment of diﬀerent cardiac pathologies such
as acute MI, chronic ischemic LV dysfunction secondary to
MI, and nonischemic dilated cardiomyopathy.
5. FuturePerspectivesof Mesenchymal Stem
Cell Therapy
Overall, preclinical and clinical data from animal mod-
els and humans have demonstrated the feasibility, safety,
and eﬃciency of MSCs therapy for cardiac regeneration.
Accordingly, MSC therapy assures myocardial repair for a
large number of heart failure patients; yet, there are several
aspects that still need to be resolved. This will need rigorous
investigation in the years to come [53]. Future studies should
focusontheeﬃciencyofMSCtherapyinanimalsatdiﬀerent
ages (adult and old), instead of young adult animals only.
Investigating the eﬃcacy of MSC treatment combined with
standard post-MI therapies, such as angiotensin converting
enzyme inhibitors and beta-blockers, is also necessary to
maximize the therapeutic beneﬁts. Subsequently, dose esca-
lation studies will be required to optimize MSC therapy
before being considered as a potential clinical treatment. It
is also important to consider the potential beneﬁts of MSC
therapy in nonischemic heart failure models rather than the
commonlyusedpost-MImodel[53].Approachestoimprove
engraftment and diﬀerentiation are required due to the low
retention of cardiac stem cells regardless of the delivery
method used. Moreover, the precise mechanism of action of
MSCs needs to be speciﬁcally deﬁned; it is still not clear if
they work through paracrine signaling, cell fusion, cell-cell
interaction, diﬀerentiation to cardiomyocytes, neovascular-
ization, and/or a combination of some or all of these eﬀects.
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Table 3: Ongoing clinical trials on MSCs: condition, intervention/dose, and followup in patients around the world
(http://www.clinicaltrials.gov).
World Condition Intervention Time frame Phase/Status
Florida (USA)
Chronic ischemic LV
dysfunction secondary to MI
10 and 20 intramyocardial injections
of 2 million MSCs (low dose) or 20
million (high dose)/0.25–0.5cm3 for a
total of 20 million or 200 million cells,
respectively
6–18 months Phase I/II (unknown)
Chronic ischemic LV
dysfunction and heart failure
secondary to MI
Transendocardial injection of
autologous human cells (bone marrow
or mesenchymal). 40 million cells/mL
delivered in either a dose of
0.25mL/injection for a total of 100
million × 10 injections or a dose of
0.5mL/injection for a total of 200
million × 10 injections
6–18 months Phase I/II (unknown)
Chronic ischemic LV
dysfunction secondary to MI
Transendocardial injection of
autologous versus allogeneic MSCs. 40
million cells/mL delivered in either a
dose of 0.5mL/injection × 1 injection
f o rat o t a lo f2 0m i l l i o n ,ad o s eo f
0.5mL/injection × 5 injections for a
total of 100 million, or a dose of
0.5mL/injection × 10 injections for a
total of 200 million MSCs
6–13 months Phase I/II (active)
Nonischemic dilated
cardiomyopathy
Transendocardial injection of
autologous versus allogeneic MSCs. 20
million cells/mL delivered in a dose of
0.5mL/injection × 10 injections for a
total of 100 million of MSCs
6–12 months Phase I/II (active)
Maryland (USA)
Chronic ischemic LV
dysfunction secondary to MI
10 and 20 intramyocardial injections
of 2 million MSCs (low dose) or 20
million (high dose)/0.25–0.5 cm3 for a
total of 20 million or 200 million of
autologous human MSCs, respectively
6–18 months Phase I/II (unknown)
Chronic ischemic LV
dysfunction secondary to MI
Transendocardial injection of
autologous versus allogeneic MSCs. 40
million cells/mL delivered in either a
dose of 0.5mL/injection × 1 injection
f o rat o t a lo f2 0m i l l i o n ,ad o s eo f
0.5mL/injection × 5 injections for a
total of 100 million, or a dose of
0.5mL/injection × 10 injections for a
total of 200 million MSCs
6–13 months Phase I/II (active)
France (Europe) Chronic myocardial ischemia;
LV dysfunction
Transendocardial intramyocardial
injections of 60 million autologous
MSCs
30 days–2 years Phase I/II (active)
China (East Asia) ST-elevation MI Intracoronary human umbilical
WJ-MSC transfer 4 months–1 year Phase II (active)
Korea (East Asia) Acute MI
Intracoronary injection of single dose
of autologous bone-marrow-derived
MSCs (I million) cells/kg
6 months Phase II (completed)
India (South Asia) ST-elevation acute MI A Single Dose of Intravenous infusion
of Allogenic MSCs 6 months Phase I/II (active)10 Stem Cells International
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